ライフサイエンスコーパス: cardiac troponin

1 Nearly all patients will have an elevated cardiac troponin.

2 yocytes between days 7 and 14, and expressed cardiac troponin.

3 Cardiac troponin and B-type natriuretic peptide (BNP) co

4 I(R146G), and cTnI(R21C) were complexed into cardiac troponin and exchanged into rat ventricular myof

5 sessment algorithm based on high-sensitivity cardiac troponin and sampling at 0 and 1 hour.

6 ype natriuretic peptide and high-sensitivity cardiac troponin), and clinical history (prior stroke).

7 Elevated levels of cardiac troponin, and especially their relative changes

8 Elevated levels of cardiac troponins are associated with adverse clinical o

9 Cardiac troponins are the preferred biomarkers for diagn

10 r of time before the use of high-sensitivity cardiac troponin assays (hs-cTn) becomes common througho

11 tected more frequently once high-sensitivity cardiac troponin assays are approved for clinical use in

12 High-sensitivity cardiac troponin assays enable myocardial infarction to

13 ) and cardiomyocyte damage using 2 different cardiac troponin assays in 718 consecutive patients pres

14 New, highly sensitive cardiac troponin assays permit evaluation of the associa

15 3 received placebo; 717 routine ECGs and 930 cardiac troponin assays were performed.

16 The improvement in cardiac troponin assays, especially in conjunction with

17 r specificity, determination of the level of cardiac troponins became a predominant indicator for MI.

18 as used to determine incorporation of mutant cardiac troponin C ( approximately 21%) into the KI-TnC-

19 Mutations in TNNC1-encoded cardiac troponin C (cTnC) are a relatively rare cause of

20 c cardiomyopathy-associated mutant D145E, in cardiac troponin C (cTnC) C-domain, causes generalised i

21 Cardiac troponin C (cTnC) is the regulatory protein that

22 ique 31-residue N-terminal region that binds cardiac troponin C (cTnC) to increase the calcium sensit

23 The Ca(2+) sensor of the sarcomere, cardiac troponin C (cTnC), plays an important role in re

24 ac thin-filament activation, the N-domain of cardiac troponin C (N-cTnC) binds to Ca(2+) and interact

25 Coincident S-nitrosylation of cardiac troponin C decreases myocardial sensitivity to C

26 ation, in general, and for phospholamban and cardiac troponin C S-nitrosylation, in particular, in be

27 The ability of calcium-bound human cardiac troponin C to neutralize the inhibition of K206I

28 nt distance from the calcium binding site in cardiac troponin C, and do not affect either the binding

29 ndling proteins, including phospholamban and cardiac troponin C, thereby playing an essential and pre

30 tivity in the absence of calcium-bound human cardiac troponin C.

31 Measurement of the cardiac troponins, cardiac troponin T and cardiac tropon

32 trated by increased myocardial injury, serum cardiac troponin, cellular infiltration, complement depo

33 main of the troponin I subunit (TnIC) of the cardiac troponin complex.

34 A cardiac troponin concentration of less than 5 ng/L ident

35 of this study was to assess associations of cardiac troponin concentration with cardiovascular disea

36 September 2016, reporting on associations of cardiac troponin concentration with first-ever CVD outco

37 In the general population, high cardiac troponin concentration within the normal range i

38 Cardiac troponin concentrations are used to identify pat

39 patients with renal impairment and elevated cardiac troponin concentrations had a 2-fold greater ris

40 S pathway incorporating low high-sensitivity cardiac troponin concentrations rules out myocardial inf

41 thway with a pathway that incorporates lower cardiac troponin concentrations to risk stratify patient

42 The introduction of high-sensitivity cardiac troponin (cTn) assays has improved sensitivity f

43 It is unknown whether more sensitive cardiac troponin (cTn) assays maintain their clinical ut

44 Cardiac troponin (cTn) is a biomarker of myocardial dama

45 Cardiac troponin (cTn) is a key molecule in the regulati

46 Measures of cardiac troponin (cTn) may have lower specificity for my

47 ropriate clinical decision values (CDVs) for cardiac troponin (cTn) owing to limitations in the curre

48 ues 1-40) has not been resolved in the whole cardiac troponin (cTn) structure, little is known about

49 of FHC-related mutations are found in cTnT [cardiac troponin (cTn) T].

50 This study sought to review cardiac troponin (cTn) trends during non-ST-segment elev

51 estricted protein that is more abundant than cardiac troponins (cTn) and is released more rapidly aft

52 Cardiac troponins (cTn) may be elevated among patients w

53 schemic stroke (AIS) have elevated levels of cardiac troponins (cTn).

54 Cardiac troponin detected by new-generation, highly sens

55 was abolished by mutagenesis, and effects on cardiac troponin dynamics were mapped by hydrogen-deuter

56 G changes for pericarditis, arrhythmias, and cardiac troponin elevation or new or worsening ventricul

57 IV histone infusion caused time-dependent cardiac troponin elevation to indicate cardiac injury.

58 Circulating cardiac troponin has been associated with adverse progno

59 High-sensitivity cardiac troponin (hs-cTn) assays have been used clinical

60 myocardial infarction using high-sensitivity cardiac troponin (hs-cTn) concentrations irrespective of

61 on the association between high-sensitivity cardiac troponin (hs-cTn) levels and outcomes in patient

62 a modified HEART score </=3 (which includes cardiac troponin I <0.04 ng/mL at 0 and 3 hours) were ra

63 fabricated with an immobilized antibody for cardiac troponin I (anti-cTnI) on a photoresponsive comp

64 dots (afGQDs) conjugated with antibody anti-cardiac Troponin I (anti-cTnI) to detect cardiac marker

65 farction (AMI) when used in combination with cardiac troponin I (cTnI) <99 th percentile and a nondia

66 most specific markers for cardiac injury are cardiac troponin I (cTnI) and cardiac troponin T (cTnT)

67 ing in PKA-site dependent phosphorylation of cardiac troponin I (cTnI) and phospholamban (PLN).

68 Practice guidelines regard cTnT and cardiac troponin I (cTnI) as equally sensitive and speci

69 formance metrics of a novel high-sensitivity cardiac troponin I (cTnI) assay for this purpose.

70 )O(4) MNPs in the enhancement of LSPR assay, cardiac troponin I (cTnI) for myocardial infarction diag

71 Cardiac troponin I (cTnI) functions as the molecular swi

72 During beta-adrenergic stimulation, cardiac troponin I (cTnI) is phosphorylated by protein k

73 Both tobacco smoking and circulating cardiac troponin I (cTnI) levels are associated with the

74 Two hypertrophic cardiomyopathy-associated cardiac troponin I (cTnI) mutations, R146G and R21C, are

75 t proteins revealed site-specific changes in cardiac Troponin I (cTnI) phosphorylation, as well as a

76 , which coincided with a similar increase in cardiac troponin I (cTnI) protein, the established marke

77 The cardiac troponin I (cTnI) R145W mutation is associated w

78 The cardiac troponin I (cTnI) R21C (cTnI-R21C) mutation has

79 Cardiac troponin I (cTnI) was measured by using a novel,

80 ition, a competitive binding assay to detect cardiac Troponin I (cTnI) was used as an example to demo

81 highly sensitive and label-free detection of cardiac troponin I (cTnI), a biomarker for diagnosis of

82 PKA targets the N-terminus (Ser-23/24) of cardiac troponin I (cTnI), cardiac myosin-binding protei

83 ncluding titin, myosin-binding protein-C and cardiac troponin I (cTnI), we sought to define if phosph

84 osed for the ultrasensitive immunosensing of Cardiac Troponin I (cTnI).

85 quantities of monoclonal antibodies against cardiac troponin I (cTnI).

86 myocardial infarction using high-sensitivity cardiac troponin I (hs-cTnI) have been identified.

87 c troponin T (hs-cTnT), and high-sensitivity cardiac troponin I (hs-cTnI) were determined in plasma s

88 Quartiles of BNP and high-sensitivity cardiac troponin I (hs-cTnI) were included in adjusted m

89 High-sensitivity cardiac troponin I (hs-TnI) levels at baseline were asse

90 tionship between changes in high-sensitivity cardiac troponin I (hsTnI) and cardiovascular outcomes.

91 We measured high-sensitivity cardiac troponin I (hsTnI) in 12 956 and BNP in 11 076 p

92 e molecular mechanism(s) of the mutant human cardiac troponin I (K206I), we tested the Ca(2+) depende

93 Cardiac troponin T (cTnT) and sensitive cardiac troponin I (s-cTnI) were also significantly high

94 rminal domain novel phosphorylation sites of cardiac troponin I (S165, T180, S198).

95 with mice expressing a pseudophosphorylated cardiac troponin I (S23D and S24D; TnI-PP).

96 sites located in the N-terminal extension of cardiac troponin I (S4, S5, Y25), an increase in phospho

97 Autoimmune response to cardiac troponin I (TnI) induces inflammation and fibros

98 e is a progressive increase in expression of cardiac troponin I (TnI), with a concurrent decrease in

99 KEY POINTS: Mutations in genes encoding cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2

100 : the sarcomeric mutations in genes encoding cardiac troponin I (TNNI3p.98truncation ) and cardiac tr

101 ors showed extraordinary sensitivity towards cardiac troponin I [1.7microA/(ng/mL) in phosphate buffe

102 ssociated with PAPP-A stratified by baseline cardiac troponin I [Accu-TnI >0.04 mug/l], p interaction

103 ning reduces the incidence of postprocedural cardiac troponin I after elective PCI and confers an MAC

104 Patients with an MACCE had a higher mean cardiac troponin I after PCI (+/-SD): 2.07+/-6.99 versus

105 rary primary prevention population, baseline cardiac troponin I and BNP were associated with the risk

106 n of CMBK resulted in higher serum levels of cardiac troponin I and elevated amounts of reactive oxyg

107 ncreased expression of the maturation marker cardiac troponin I and significantly increased action po

108 vels of B-type natriuretic peptide (BNP) and cardiac troponin I are associated with adverse outcomes

109 xhibits five times lower detection limit for cardiac troponin I assay with a high selectivity.

110 ons at presentation using a high-sensitivity cardiac troponin I assay.

111 ntervention for such patients, the dosage of cardiac troponin I at admission could not help in the de

112 roperties and still enabled the detection of cardiac troponin I at pg/mL concentrations in 10% serum

113 us biomolecular recognition of model analyte cardiac troponin I by two antibody fragments brought the

114 rched to evaluate if an early measurement of cardiac troponin I can help to detect a recent coronary

115 acute coronary syndrome, a high-sensitivity cardiac troponin I concentration of less than 5 ng/L ide

116 Plasma cardiac troponin I concentration was measured with a hig

117 e myocardial injury (high-sensitivity plasma cardiac troponin I concentration, 4.3 ng/L [interquartil

118 y, as assessed by serial measurements of the cardiac troponin I concentration.

119 consecutive patients (n=2122) with elevated cardiac troponin I concentrations (>/=0.05 microg/L) at

120 ocardial ischemia, and an increase in plasma cardiac troponin I concentrations (1.4 [0.8-2.5] versus

121 ospective studies measuring high-sensitivity cardiac troponin I concentrations in patients with suspe

122 Cardiac troponin I concentrations were less than 5 ng/L

123 Low concentrations of high-sensitivity cardiac troponin I determined on presentation to the eme

124 We discuss a current concept of cardiac troponin I function in the A-band region of the

125 of the sarcomere and potential signaling to cardiac troponin I in a network involving the ends of th

126 terferences when electrochemically detecting cardiac troponin I in complex biological samples.

127 terations occurred on individual residues of cardiac troponin I in heart failure, likely reflecting a

128 valuated the performance of high-sensitivity cardiac troponin I in those with and without renal impai

129 We review how phosphorylation signaling to cardiac troponin I is integrated, with parallel signals

130 Cardiac troponin I levels were normal in all patients, w

131 study were to assess the prognostic value of cardiac troponin I levels, measured with a new high-sens

132 lic groups used to immobilise antibodies for cardiac troponin I marker.

133 syndrome (n=1218) underwent high-sensitivity cardiac troponin I measurement at presentation and 3 and

134 rds measured in transgenic mice expressing a cardiac troponin I mutation (R145G).

135 l injury as indicated by a positive test for cardiac troponin I or troponin T.

136 the modulation of thin filament activity by cardiac troponin I phosphorylation as an integral and ad

137 ural symptoms, ECG ST-segment deviation, and cardiac troponin I release after elective PCI and reduce

138 Periprocedural cardiac troponin I significantly increased (F=3.64; P=0.

139 r the interaction between the Ca(2+) ion and cardiac troponin I subunit.

140 High-sensitivity cardiac troponin I testing is widely used to evaluate pa

141 f peptides afforded higher sensitivities for cardiac troponin I than those prepared by the chemisorpt

142 To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at presentation a

143 high sensitivity assay for the detection of cardiac troponin I using electrical double layer gated h

144 count and myocardial blush grade), and serum cardiac troponin I were assessed before and after PCI.

145 rs of a recent coronary occlusion (including cardiac troponin I) and their respective contribution.

146 ication of cardiac biomarkers (myoglobin and cardiac troponin I) in the clinically significant sensin

147 199 (equivalent to Ser200 in mouse) of cTnI (cardiac troponin I) is significantly hyperphosphorylated

148 tinin, cardiac myosin-binding protein C, and cardiac troponin I).

149 The device can detect serum cardiac troponin I, a biomarker of cardiac disease to 10

150 implified Pulmonary Embolism Severity Index, cardiac troponin I, brain natriuretic peptide, and lower

151 ompe disease, the relationship between cTnT, cardiac troponin I, creatine kinase (CK), CK-myocardial

152 Cardiac troponin I, N-terminal pro-B-type natriuretic pe

153 s: Risk score and clinical outcomes based on cardiac troponin I, N-terminal pro-B-type natriuretic pe

154 t amplitude but decreased phosphorylation of cardiac troponin I, suggesting direct effects on the con

155 system has been applied to the detection of cardiac Troponin I, the gold standard biomarker for the

156 he cardiac troponins, cardiac troponin T and cardiac troponin I, using sensitive methods, defines a t

157 A series of cardiac troponin I-interacting kinase (TNNI3K) inhibitor

158 r Tm180 littermates, which express wild-type cardiac troponin I.

159 letal troponin I but not when it is bound to cardiac troponin I.

160 High-sensitivity assays can quantify cardiac troponins I and T (hs-cTnI, hs-cTnT) in individu

161 oped for rapid and simultaneous screening of cardiac Troponin-I (cTnI) and cardiac-Troponin-T (cTnT)

162 RNA signatures correlated with elevations in cardiac Troponin-I in severely injured hearts during EVH

163 F) nanoelectrode arrays for the detection of cardiac troponin-I in the early diagnosis of myocardial

164 ther confirmed by a significant reduction of cardiac troponin-I release and less myocardial apoptosis

165 gens, like cardiac myosin heavy chain-alpha, cardiac troponin-I, and adenine nucleotide translocator

166 ed acute coronary syndrome, high-sensitivity cardiac troponin identified fewer patients with renal im

167 Elevation of baseline cardiac troponin in patients presenting with acute coron

168 of a large proportion of patients with minor cardiac troponin increases (14 to 49 ng/l), the majority

169 The basal phosphorylation of cardiac troponin inhibitor (cTnI) and the myosin-binding

170 Cardiac troponin is an independent predictor of cardiova

171 Cardiac troponin is the preferred biomarker for diagnosi

172 Cardiac troponin levels are often detectable in communit

173 ed mice at 24 hours, Ppara mice had elevated cardiac troponin levels compared with wild-type mice.

174 Circulating histones and cardiac troponin levels were obtained from serial blood

175 t size), a Biomarker Core (to measure plasma cardiac troponin levels), and a Data Coordinating Center

176 ble physiological effects (without affecting cardiac troponin levels), but short-term treatment did n

177 morphometry, neutrophil accumulation, blood cardiac troponin levels, and echocardiography and observ

178 ng, and cardiac biomarkers (high-sensitivity cardiac troponins, NT-proBNP [N-terminal pro-B-type natr

179 nal function, and the blood concentration of cardiac troponin often increases with declining glomerul

180 IMI risk scores, which incorporate the first cardiac troponin, provided more diagnostic information.

181 Minimally elevated serum cardiac troponin reflects myocardial injury and is assoc

182 ative myocardial injury and death, measuring cardiac troponin routinely after noncardiac surgery has

183 and altered stoichiometry between the three cardiac troponin subunits.

184 Cardiac troponin T (cTnT) and sensitive cardiac troponin

185 Abstract Cardiac troponin T (cTnT) has a highly acidic extended N

186 ical and biological significance of elevated cardiac troponin T (cTnT) in patients with neuromuscular

187 Cardiac troponin T (cTnT) is a key component of contract

188 Changes in cardiac troponin T (cTnT) levels are required for the di

189 erified assumption that chronically elevated cardiac troponin T (cTnT) levels fluctuate randomly arou

190 Elevated plasma cardiac troponin T (cTnT) levels in patients with neurom

191 Serum creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT) levels were measured before an

192 embled on a screen-printed electrode for the cardiac troponin T (cTnT) was developed.

193 esent study was to evaluate whether elevated cardiac troponin T (cTnT) was independently associated w

194 Repeated measures of highly sensitive cardiac troponin T (cTnT) were obtained in participants

195 iac injury are cardiac troponin I (cTnI) and cardiac troponin T (cTnT) which have been considered as

196 isopropylacrylamide (PNIPAAm) functionalised cardiac troponin T (cTnT) with anti-cTnT.

197 splicing of TNNT2, the gene that encodes for cardiac troponin T (cTnT), a biomarker of myocardial inj

198 interaction between LVH, low but detectable cardiac troponin T (cTnT), and elevated N-terminal pro-B

199 Cardiac troponin T (cTnT), even at low concentrations, i

200 er Nkx2.5, or that of the myocardial marker, cardiac troponin T (cTnT).

201 rdial infarction, especially with the use of cardiac troponin T (cTnT).

202 tiation factor-15 (GDF-15), high-sensitivity cardiac troponin T (cTnT-hs) and haemoglobin, age, and p

203 cardiograms and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-t

204 anterior circulation and a high-sensitivity cardiac troponin T (hs-cTnT) acquired on the day of admi

205 Although small elevations of high-sensitive cardiac troponin T (hs-cTnT) are associated with inciden

206 High-sensitivity assays for cardiac troponin T (hs-cTnT) are sometimes used to rapid

207 tional level, with elevated high-sensitivity cardiac troponin T (hs-cTnT) concentrations (>/=14 ng/L)

208 tic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations were measure

209 rognostic value of baseline high-sensitivity cardiac troponin T (hs-cTnT) elevation in SCAD patients

210 ated hemoglobin (HbA1c) and high-sensitivity cardiac troponin T (hs-cTnT) in 9,661 participants free

211 sponse to mental stress and high-sensitivity cardiac troponin T (hs-cTnT) in healthy older individual

212 implications of introducing high-sensitivity cardiac troponin T (hs-cTnT) into clinical practice and

213 High-sensitivity cardiac troponin T (hs-cTnT) is a biomarker of cardiovas

214 f an undetectable (<5 ng/l) high-sensitivity cardiac troponin T (hs-cTnT) level and an electrocardiog

215 hesized that any detectable high-sensitivity cardiac troponin T (hs-cTnT) level is associated with ad

216 s are preferable when using high-sensitivity cardiac troponin T (hs-cTnT) levels in the diagnosis of

217 Their high-sensitivity cardiac troponin T (hs-cTnT) levels were measured.

218 econdary endpoints included high-sensitivity cardiac troponin T (hs-cTnT) on day 4, left ventricular

219 A 1-h algorithm based on high-sensitivity cardiac troponin T (hs-cTnT) testing at presentation and

220 Thus, we assessed whether high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical my

221 B-type natriuretic peptide, high-sensitivity cardiac troponin T (hs-cTnT), and high-sensitivity cardi

222 uretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotei

223 ognostic merit with that of high-sensitivity cardiac troponin T (hs-TnT).

224 We also reconstituted mouse cardiac troponin T (McTnT) N-terminal deletion mutants,

225 eri-procedural increases of high-sensitivity cardiac troponin T (mean: 9.9 ng/ml, range: 2.7 to 19.0

226 enes encoding cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2) caused altered troponin prote

227 RNAs including the Insulin Receptor (Insr), Cardiac Troponin T (Tnnt2), Lim Domain Binding 3 (Ldb3)

228 ardiac troponin I (TNNI3p.98truncation ) and cardiac troponin T (TNNT2p.K217deletion ; also known as

229 Cardiac troponin T (TnT) is a highly sensitive cardiac b

230 are mutations in the TNNT2 gene that encodes cardiac troponin T (TnT).

231 Adding high-sensitive cardiac troponin T absolute change to the Revised Cardia

232 protein expression of cardiomyogenic markers cardiac troponin T and alpha-smooth muscle actin in CPCe

233 Measurement of the cardiac troponins, cardiac troponin T and cardiac troponin I, using sensiti

234 High-sensitivity cardiac troponin T and creatine kinase-myocardial band w

235 he 2 well-known biomarkers (high-sensitivity cardiac troponin T and N-terminal pro-brain natriuretic

236 ment of beating sheets of cells that express cardiac troponin T and show a full range of action poten

237 ype natriuretic peptide and high-sensitivity cardiac troponin T are frequently elevated in severe sep

238 per reference limit for the high-sensitivity cardiac troponin T assay (hs-cTnT) in 3 large independen

239 With the widespread use of high-sensitive cardiac troponin T assays, positive tests become frequen

240 17.8 ng/L and a perioperative high-sensitive cardiac troponin T change greater than or equal to 6.3 n

241 The risk predictive power of high-sensitive cardiac troponin T change in addition to the Revised Car

242 We measured the cardiac troponin T concentration at baseline with a high

243 The cardiac troponin T concentration was an independent pred

244 type natriuretic peptide or high-sensitivity cardiac troponin T concentrations were independently ass

245 Elevated cardiac troponin T even below traditional detection leve

246 mano-Ward syndrome and long-QT syndrome, and cardiac troponin T gene, tnnt2, affected in human cardio

247 A preoperative high-sensitive cardiac troponin T greater than or equal to 17.8 ng/L an

248 n 97.4% of the patients and high-sensitivity cardiac troponin T in 84.5%, with higher concentrations

249 sing serial measurements of high-sensitivity cardiac troponin T in clinical routine.

250 was defined as an absolute high-sensitivity cardiac troponin T increase of >/=14 ng/L from preoperat

251 Deletion of the 14 C-terminal residues of cardiac troponin T leads to hypertrophic cardiomyopathy.

252 Serum high-sensitivity cardiac troponin T levels and electrocardiograms were ob

253 However, changes in cardiac troponin T levels during the infusion did not di

254 acrophages, almost complete normalization of cardiac troponin T levels in serum and of left ventricul

255 In patients with NSTE-ACS and elevated cardiac troponin T levels, an early invasive strategy ha

256 ive and 24-hour postoperative high-sensitive cardiac troponin T measurements and the respective chang

257 Pre- and postoperative high-sensitive cardiac troponin T measurements demonstrated a majority

258 In addition, two mouse cardiac troponin T mutants (TnT(1-44Delta) and TnT(45-74

259 10(-8)) in the gene TNNT2, which encodes the cardiac troponin T protein itself.

260 ociation rates in fully reconstituted WT and cardiac troponin T R92L and R92W thin filaments.

261 and methylprednisolone significantly reduced cardiac troponin T release and the number of allograft i

262 nhanced myocardial damage evidenced by serum cardiac troponin T release in the rat and mouse cardiac

263 pro-brain natriuretic peptide (pro-BNP), and cardiac troponin T showed significant linear trends for

264 h no cardiovascular disease in our study had cardiac troponin T values above the current myocardial i

265 High-sensitivity cardiac troponin T was measured as a marker of myocardia

266 The level of high-sensitive cardiac troponin T was significantly associated with pre

267 ype natriuretic peptide and high-sensitivity cardiac troponin T were measured 1, 2, and 7 days after

268 We measured cardiac troponin T with a highly sensitive assay (hs-cTn

269 hich most patients would have had a negative cardiac troponin T with older assays); and Group 4, thos

270 rmined pre- and postoperative high-sensitive cardiac troponin T with the occurrence of major adverse

271 Pretransplant cardiac troponin T(cTnT(pre) ) is a significant predicto

272 nges in markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C),

273 144 patients with elevated high-sensitivity cardiac troponin T, 31 had signs of MI and 113 did not.

274 Levels of cardiac troponin T, a biomarker of cardiomyocyte injury,

275 B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive prot

276 B-type natriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive prot

277 pe natriuretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated

278 For a third trait, cardiac troponin T, investigation of regulatory domains

279 High levels of cardiac troponin T, measured by a highly sensitive assay

280 coronary syndrome (NSTE-ACS) and an elevated cardiac troponin T.

281 1,200 patients with NSTE-ACS and an elevated cardiac troponin T.

282 (endo)plasmic reticulum Ca(2+) ATPase 1, and cardiac troponin T.

283 gy in patients with NSTE-ACS and an elevated cardiac troponin T.

284 -day mortality, better than high-sensitivity cardiac troponin T.

285 nano-gap device provides the capability for cardiac-troponin T (cTnT) measurements with co-existed 1

286 Cardiac Troponins (T and I) are well established protein

287 the pathologic free light chains (p < 0.05), cardiac troponin-T (cTnT) (p < 0.01), and the Karnofsky

288 through the detection and quantification of cardiac Troponin-T (cTnT).

289 rdial Infarction) evaluated high-sensitivity cardiac troponin-T (hs-cTnT) in a 1-hour acute myocardia

290 th myocardial damage (using high-sensitivity cardiac troponin-T [hs-cTnT]) and with coronary heart di

291 rdiac-selective expression of EcSOD from the cardiac troponin-T promoter after systemic administratio

292 ellular superoxide dismutase (EcSOD) via the cardiac troponin-T promoter would protect the mouse hear

293 ificantly more cardiomyocytes, determined by cardiac troponin-T staining, in the MI zone of the QHG21

294 Left ventricular structure and function and cardiac troponin-T were among the top predictors for inc

295 tions between or near residues 112 to 136 of cardiac troponin-T, the crucial TnT1 (N-terminal domain

296 s screening of cardiac Troponin-I (cTnI) and cardiac-Troponin-T (cTnT) in a point-of-care sensor form

297 (RV) dysfunction on imaging, and a positive cardiac troponin test result.

298 High-sensitivity cardiac troponin testing may improve the risk stratifica

299 ectrochemical sensor platform for monitoring cardiac troponins through the detection and quantificati

300 Cardiac troponin was detectable in 80.0% (hs-cTnI: 82.6%